Mayo Clinic Laboratory and Pathology Research Roundup: Jan. 22

By Kelley Luedke • January 22, 2018

Share this:

The Research Roundup provides an overview of the past week’s research from Mayo Medical Laboratories consultants, including featured abstracts and complete list of published studies and reviews.

Featured Abstract

Improving Immune-Vascular Crosstalk for Cancer Immunotherapy

The vasculature of tumors is highly abnormal and dysfunctional. Consequently, immune effector cells have an impaired ability to penetrate solid tumors and often exhibit compromised functions. Normalization of the tumor vasculature can enhance tissue perfusion and improve immune effector cell infiltration, leading to immunotherapy potentiation. However, recent studies have demonstrated that the stimulation of immune cell functions can also help to normalize tumor vessels. In this article, Mayo Clinic researchers propose that the reciprocal regulation between tumor vascular normalization and immune reprogramming forms a reinforcing loop that reconditions the tumor immune microenvironment to induce durable anti-tumor immunity. A deeper understanding of these pathways could pave the way for identifying new biomarkers and developing more effective combination treatment strategies for patients with cancer. The study was published in Nature Reviews: Immunology.

Published to PubMed This Week

• • Meta-Analyses and Interpretation of Troponin Values in Heart Failure
    JACC: Heart Failure
  • Glutamine-Derived 2-Hydroxyglutarate is Associated with Disease Progression in Plasma Cell Malignancies
    JCI Insight
  • A Distance-Based Approach for Testing the Mediation Effect of the Human Microbiome
    Bioinformatics
  • Normal Karyotype in Myelofibrosis: Is Prognostic Integrity Affected by the Number of Metaphases Analyzed?
    Blood Cancer Journal
  • Bulbar Conjunctival Nodule in a Patient With Rheumatoid Arthritis
    JAMA Ophthalmology
  • De Novo Pure Erythroid Leukemia: Refining the Clinicopathologic and Cytogenetic Characteristics of a Rare Entity
    Modern Pathology
  • Pharmacokinetics of Rituximab and Clinical Outcomes in Patients with Anti-Neutrophil Cytoplasmic Antibody Associated Vasculitis
    Rheumatology
  • Prospective Trial Evaluating the Sensitivity and Specificity of 3,4-dihydroxy-6-[18F]-fluoro-L-phenylalanine (18F-DOPA) PET and MRI in Patients with Recurrent Gliomas
    Journal of Neuro-Oncology
  • Adenovirus Platform Enhances Transduction Efficiency of Human Mesenchymal Stem Cells: An Opportunity for Cellular Carriers of Targeted TRAIL-based TR3 Biologics in Ovarian Cancer
    PLoS One
  • A Lack of Systemic Absorption Following the Repeated Application of Topical Quetiapine in Healthy Adults
    American Journal of Hospice and Palliative Medicine
  • A Severe Case of Congenital Thrombotic Thrombocytopenia Purpura Resulting From Compound Heterozygosity Involving a Novel ADAMTS13 Pathogenic Variant
    Journal of Pediatric Hematology/Oncology

Kelley Luedke

Kelley Luedke is a Marketing Channel Manager at Mayo Clinic Laboratories. She is the principle editor and writer of Insights and leads social media and direct marketing strategy. Kelley has worked at Mayo Clinic since 2013. Outside of work, you can find Kelley running, traveling, playing with her kitty, and exploring new foods.